Headline: Biogen (BIIB) Acquires RayThera for $1 Billion, Expands Immunology Pipeline

Biogen (BIIB) announced on June 18, 2026, its acquisition of RayThera for $1 billion. The deal aims to significantly expand Biogen's immunology pipeline, particularly with RayThera's lead asset, RT-001, a promising treatment for autoimmune diseases. The acquisition includes an upfront payment and potential milestone payments. RayThera's RT-001, currently in Phase 2 trials, targets several chronic inflammatory conditions, representing a strategic move for Biogen to diversify beyond its neurology focus. This transaction underscores Biogen's commitment to strengthening its presence in the immunology market.